These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 17296817)

  • 1. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of epidermal growth factor receptor in cancer metastasis and microenvironment.
    Sasaki T; Hiroki K; Yamashita Y
    Biomed Res Int; 2013; 2013():546318. PubMed ID: 23986907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors.
    Roy M; Luo YH; Ye M; Liu J
    Biomed Res Int; 2013; 2013():964743. PubMed ID: 23936861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.
    Krawczyk P; Mlak R; Powrózek T; Nicoś M; Kowalski DM; Wojas-Krawczyk K; Milanowski J
    Contemp Oncol (Pozn); 2012; 16(5):401-6. PubMed ID: 23788917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.
    de Mello RA; Marques DS; Medeiros R; Araújo AM
    World J Clin Oncol; 2011 Nov; 2(11):367-76. PubMed ID: 22087435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.
    Spicer JF; Rudman SM
    Target Oncol; 2010 Dec; 5(4):245-55. PubMed ID: 20574858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.
    Siwak DR; Carey M; Hennessy BT; Nguyen CT; McGahren Murray MJ; Nolden L; Mills GB
    J Oncol; 2010; 2010():568938. PubMed ID: 20037743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer.
    Casorzo L; Corigliano M; Ferrero P; Venesio T; Risio M
    Diagn Pathol; 2009 Nov; 4():36. PubMed ID: 19889201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neglected respiratory toxicity caused by cancer therapy.
    Domingo C; Roig J
    Open Respir Med J; 2007; 1():1-6. PubMed ID: 19340316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
    Kuwai T; Nakamura T; Sasaki T; Kim SJ; Fan D; Villares GJ; Zigler M; Wang H; Bar-Eli M; Kerbel RS; Fidler IJ
    Neoplasia; 2008 May; 10(5):489-500. PubMed ID: 18472966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR FISH versus mutation: different tests, different end-points.
    Cappuzzo F
    Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.
    Sartori G; Cavazza A; Sgambato A; Marchioni A; Barbieri F; Longo L; Bavieri M; Murer B; Meschiari E; Tamberi S; Cadioli A; Luppi F; Migaldi M; Rossi G
    Am J Clin Pathol; 2009 Apr; 131(4):478-89. PubMed ID: 19289583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
    Jänne PA
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.
    Toschi L; Cappuzzo F
    Oncologist; 2007 Feb; 12(2):211-20. PubMed ID: 17296817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.